Database Query Results : diet Short Term Fasting, ,

dietSTF, diet Short Term Fasting: Click to Expand ⟱
Features:
Short-term fasting (STF) 48 to 72 h before chemotherapy appears to be more effective than intermittent fasting. Preliminary data show that STF is safe but challenging in cancer patients receiving chemotherapy.

Short-Term Fasting (STF; ~24–72 h water / very low calorie fast) Cancer vs Normal Cell Effects
Rank Pathway / Axis Cancer Cells Normal Cells Label Primary Interpretation Notes
1 Insulin / IGF-1 signaling ↓ IGF-1 survival signaling (stress) ↓ IGF-1 with adaptive protection Driver Differential stress resistance (DSR) Cancer cells fail to adapt to acute IGF-1 withdrawal; normal cells enter protective mode
2 AMPK → mTOR nutrient sensing ↑ AMPK; ↓ mTOR (growth crisis) ↑ AMPK; ↓ mTOR (protective quiescence) Driver Catabolic enforcement Rapid mTOR suppression removes anabolic support from tumors
3 Autophagy (ATG program) ↑ autophagy → metabolic exhaustion ↑ autophagy → cytoprotection Driver Catabolic stress vs survival recycling Autophagy is protective in normal cells but destabilizing in cancer cells
4 Mitochondrial metabolism / flexibility ↓ metabolic flexibility; ↓ ATP resilience ↑ mitochondrial efficiency Secondary Energy crisis vs optimization Tumors struggle to switch fuels; normal cells adapt
5 Reactive oxygen species (ROS) ↑ ROS (secondary to energy stress) ↓ ROS Secondary Metabolic redox divergence ROS increase is indirect, arising from metabolic collapse
6 NRF2 antioxidant response ↔ or insufficient activation ↑ NRF2 (protective) Adaptive Stress buffering in normal cells Normal cells activate antioxidant defenses; tumors often cannot
7 Cell cycle / proliferation ↓ proliferation / ↑ arrest ↓ proliferation (protective quiescence) Phenotypic Growth suppression Cell-cycle slowdown reflects upstream nutrient deprivation
8 Therapy sensitivity (chemo / RT) ↑ sensitivity ↓ toxicity Phenotypic Differential stress sensitization STF selectively sensitizes tumors while protecting normal tissue

Fasting Type vs Effectiveness
Fasting Type Definition Primary Metabolic / Signaling Effects Cancer-Relevant Mechanisms Evidence Base Relative Effectiveness*
Caloric Restriction (CR) Chronic daily reduction in total caloric intake (typically 20–40%) without malnutrition. ↓ insulin, ↓ IGF-1, ↓ mTOR, ↑ AMPK, ↑ autophagy Reduces growth signaling; improves metabolic milieu; may slow tumor initiation/growth in models. Extensive animal data; observational human data. Moderate–High
Caloric Restriction Mimetic (CRM) Non-fasting interventions that mimic CR signaling without major calorie reduction. ↓ mTOR, ↑ AMPK, ↑ autophagy; altered acetyl-CoA/epigenetic tone (context-dependent) Replicates key CR pathways while preserving nutrition; potential synergy with therapy (context-specific). Strong mechanistic + preclinical; growing human data. Moderate–High
Intermittent Fasting (IF) Regular cycles of fasting and feeding (e.g., 16:8, 18:6, 20:4). Periodic ↓ insulin/IGF-1; ↑ fat oxidation; mild ketosis (variable) Metabolic stress on tumor cells; improved insulin sensitivity; may modulate inflammation. Good animal data; emerging human data. Moderate
Alternate-Day Fasting (ADF) Alternating 24 h fasting with 24 h ad libitum feeding. Strong oscillations in insulin/glucose/ketones; improved metabolic switching Enhanced metabolic flexibility; may promote normal-cell stress resistance. Animal data strong; limited oncology-specific human data. Moderate–High
Short-Term Fasting (STF) Complete or near-complete fasting for ~24–72 h (often around therapy). Sharp ↓ IGF-1; ↓ glucose; ↑ ketones; ↑ autophagy Differential stress resistance (normal-cell protection) and potential tumor sensitization (context-specific). Strong preclinical; small human trials. High
Fasting-Mimicking Diet (FMD) Low-calorie, low-protein, low-sugar diet for 3–5 days designed to simulate fasting. ↓ IGF-1; ↓ mTOR; ↑ autophagy; partial ketosis Similar benefits to STF with improved tolerability; may enhance therapy response in some contexts. Strong animal; increasing human interventional data. High
Protein Restriction (PR) Reduction in total protein or specific amino acids (e.g., methionine restriction). ↓ IGF-1; ↓ mTORC1; altered amino-acid sensing Targets amino-acid dependencies and growth signaling; may synergize with selected therapies. Strong mechanistic; animal + early human data. Moderate–High
Ketogenic / Very-Low-Carb Diet Diet inducing sustained ketosis without fasting (variable protein content). ↓ glucose; ↓ insulin; ↑ ketones May constrain glycolysis-dependent tumors; effects are heterogeneous by cancer type and context. Mixed animal data; heterogeneous human data. Low–Moderate
Time-Restricted Feeding (TRF) Fixed daily eating window (typically 6–12 h), emphasizing circadian alignment. Circadian stabilization; modest ↓ insulin exposure; partial metabolic switching Improves metabolic control; limited deep autophagy unless fasting is long (≥18–20 h). Early-stage; indirect oncology evidence. Low–Moderate
Water-Only Prolonged Fasting Extended complete fasting (>72 h). Deep ketosis; strong autophagy; high physiological stress Potentially strong tumor stress but higher risk and limited controlled oncology study. Limited / heterogeneous; safety considerations significant. Uncertain / Not Rated 
Notes on Effectiveness Ratings
-High: Consistent preclinical efficacy + mechanistic clarity + early human interventional support
-Moderate–High: Strong biology with partial human validation
-Moderate: Solid rationale but limited oncology-specific human data
-Low–Moderate: Indirect or context-dependent effects
-Uncertain: Insufficient or high-risk evidence base
TRF Pattern Feeding Window Fasting Duration Metabolic Depth Cancer-Relevant Effects
14:10 TRF 10 h eating / 14 h fast 14 h Mild Improves insulin sensitivity; typically minimal autophagy.
16:8 TRF 8 h eating / 16 h fast 16 h Mild–Moderate Reduces daily insulin/IGF-1 exposure; partial metabolic switching.
18:6 TRF 6 h eating / 18 h fast 18 h Moderate Greater fat oxidation; autophagy initiation more likely (variable).
20:4 TRF 4 h eating / 20 h fast 20 h Moderate–High Lower insulin for longer; early ketosis in some individuals; more “fasting-like.”
22:2 TRF 2 h eating / 22 h fast 22 h High (borderline IF) Strong circadian + metabolic stress; limited tolerability for many. 
Circadian Timing (Critical for Cancer Relevance)
Early TRF (eTRF)
-Feeding window: ~07:00–15:00 or 08:00–16:00
-Superior reductions in insulin, glucose AUC, and IGF-1 signaling
-Aligns with PER/CRY, BMAL1, CLOCK oscillations
-More favorable for cancer-relevant metabolic control
Late TRF
-Feeding window: ~12:00–20:00 or later
-Weaker insulin and IGF-1 suppression
-Circadian misalignment may blunt benefits


Scientific Papers found: Click to Expand⟱
1626- dietSTF,  dietFMD,    When less may be more: calorie restriction and response to cancer therapy
- Review, Var, NA
CRM↑, ChemoSen↑, RadioS↑, eff↑, eff↑, IGF-1↓, TumCG↓, AMPK↑, eff↑, ChemoSen↑, RadioS↑, ROS↑, DNAdam↑, eff↑, HO-1↓,
3707- dietSTF,    Intermittent fasting protects against the deterioration of cognitive function, energy metabolism and dyslipidemia in Alzheimer’s disease-induced estrogen deficient rats
- in-vivo, AD, NA
*memory↑, *Aβ↓, *AST↓, *ALAT↓,
3708- dietSTF,    Fasting as a Therapy in Neurological Disease
*PGC-1α↑, *AMPK↑, *adiP↑, *glucose↓, *Insulin↓, *mTOR↓, *IL6↓, *TNF-α↓, *cognitive↑, *Inflam↓, *eff↑, *neuroP↑, ChemoSen↑, eff↓, chemoP↑, *eff↑,
3709- dietSTF,    Intermittent Fasting Protects against Alzheimer’s Disease Possible through Restoring Aquaporin-4 Polarity
- in-vitro, AD, NA
*cognitive↑, *Aβ↓, *AQPs↓, *HDAC3↓,
4159- dietSTF,  2DG,  CRMs,    Meal size and frequency affect neuronal plasticity and vulnerability to disease: cellular and molecular mechanisms
- Review, AD, NA
*BDNF↑, *HSPs↑, *eff↑,
4180- dietSTF,    Brain-derived neurotrophic factor, but not body weight, correlated with a reduction in depression scale scores in men with metabolic syndrome: a prospective weight-reduction study
- Human, Obesity, NA
*BDNF↑,
5065- dietSTF,  dietFMD,    Nutrition, GH/IGF-I Signaling, and Cancer
- Review, Var, NA
GH↓, IGF-1↓, glucose↓, IGFBP1↑, OS↑, Imm↑, neuroP↑, BMD↑, Dose↝, Risk↓, other↑, TumCP↓,
5066- dietSTF,    Intermittent and Periodic Fasting, Hormones, and Cancer Prevention
- Review, Var, NA
IGF-1↓, OS↑, AntiAge↑, glucose↓, Insulin↓,
5068- dietSTF,    mTOR-autophagy axis regulation by intermittent fasting promotes skeletal muscle growth and differentiation
- in-vivo, Nor, NA
*glucose↓, ROS↑, LC3B↑, p62↓, p‑mTOR↓, p‑AMPK↑,
5069- dietSTF,    The Role of Intermittent Fasting in the Activation of Autophagy Processes in the Context of Cancer Diseases
- Review, Var, NA
Risk↓, ChemoSen↑, RadioS↑, *Dose↝, *Dose↝, *Dose↝, *LDL↓, *CRP↓, *TNF-α↓, TumAuto↓, GLUT1↓, GLUT2↓, glucose↓, IGF-1↓, Insulin↓, mTOR↓, mTORC1↓, AMPK↑, Warburg↓, OXPHOS↑, ROS↑, DNAdam↑, JAK1↓, STAT↓, TumCP↓, QoL↑,
5070- dietSTF,    A review of fasting effects on the response of cancer to chemotherapy
- Review, Var, NA
chemoP↑, ChemoSen↑, *DNArepair↑, *Apoptosis↓, *CD8+↑, UPR↑, eff↝, TumAuto↑,
5071- dietSTF,    Unraveling the impact of intermittent fasting in cancer prevention, mitigation, and treatment: A narrative review
- Review, Var, NA - Review, AD, NA
Risk↓, TumCMig↓, IGF-1↓, TumAuto↑, Inflam↓, ChemoSen↑, Apoptosis↑, chemoP↑, *glucose↓, *AntiDiabetic↑, *cardioP↑, *LDL↓, *BP↓, *neuroP↑, *cognitive↑, *memory↑, *OS↑, *QoL↑, Imm↑, TumCG↓, ChemoSideEff↓, QoL↑,
597- VitC,  dietSTF,  GlucDep,    The Result of Vitamin C Treatment of Patients with Cancer: Conditions Influencing the Effectiveness
other↝, H2O2↑, ROS↑,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 13

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

H2O2↑, 1,   HO-1↓, 1,   OXPHOS↑, 1,   ROS↑, 4,  

Mitochondria & Bioenergetics ⓘ

Insulin↓, 2,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 2,   p‑AMPK↑, 1,   CRM↑, 1,   glucose↓, 3,   GLUT2↓, 1,   Warburg↓, 1,  

Cell Death ⓘ

Apoptosis↑, 1,  

Transcription & Epigenetics ⓘ

other↑, 1,   other↝, 1,  

Protein Folding & ER Stress ⓘ

UPR↑, 1,  

Autophagy & Lysosomes ⓘ

LC3B↑, 1,   p62↓, 1,   TumAuto↓, 1,   TumAuto↑, 2,  

DNA Damage & Repair ⓘ

DNAdam↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

GH↓, 1,   IGF-1↓, 5,   IGFBP1↑, 1,   mTOR↓, 1,   p‑mTOR↓, 1,   mTORC1↓, 1,   STAT↓, 1,   TumCG↓, 2,  

Migration ⓘ

TumCMig↓, 1,   TumCP↓, 2,  

Barriers & Transport ⓘ

GLUT1↓, 1,  

Immune & Inflammatory Signaling ⓘ

Imm↑, 2,   Inflam↓, 1,   JAK1↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 6,   Dose↝, 1,   eff↓, 1,   eff↑, 4,   eff↝, 1,   RadioS↑, 3,  

Clinical Biomarkers ⓘ

BMD↑, 1,  

Functional Outcomes ⓘ

AntiAge↑, 1,   chemoP↑, 3,   ChemoSideEff↓, 1,   neuroP↑, 1,   OS↑, 2,   QoL↑, 2,   Risk↓, 3,  
Total Targets: 48

Pathway results for Effect on Normal Cells:


Mitochondria & Bioenergetics ⓘ

Insulin↓, 1,   PGC-1α↑, 1,  

Core Metabolism/Glycolysis ⓘ

adiP↑, 1,   ALAT↓, 1,   AMPK↑, 1,   glucose↓, 3,   LDL↓, 2,  

Cell Death ⓘ

Apoptosis↓, 1,  

Protein Folding & ER Stress ⓘ

HSPs↑, 1,  

DNA Damage & Repair ⓘ

DNArepair↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

HDAC3↓, 1,   mTOR↓, 1,  

Barriers & Transport ⓘ

AQPs↓, 1,  

Immune & Inflammatory Signaling ⓘ

CRP↓, 1,   IL6↓, 1,   Inflam↓, 1,   TNF-α↓, 2,  

Synaptic & Neurotransmission ⓘ

BDNF↑, 2,  

Protein Aggregation ⓘ

Aβ↓, 2,  

Drug Metabolism & Resistance ⓘ

Dose↝, 3,   eff↑, 3,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   AST↓, 1,   BP↓, 1,   CRP↓, 1,   IL6↓, 1,  

Functional Outcomes ⓘ

AntiDiabetic↑, 1,   cardioP↑, 1,   cognitive↑, 3,   memory↑, 2,   neuroP↑, 2,   OS↑, 1,   QoL↑, 1,  

Infection & Microbiome ⓘ

CD8+↑, 1,  
Total Targets: 34

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:226  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page